TrialPloS one2016

A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3.

David B Shultz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.